#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cerebral arteriovenous malformation haemorrhagic Dementia Alzheimer's type Follicular lymphoma stage I Infantile apnoea Cervix carcinoma recurrent Hypereosinophilic syndrome Autoimmune myositis Subdural haematoma Emphysema Kawasaki's disease Pancreatic carcinoma Inclusion body myositis Necrotising myositis Adult T-cell lymphoma/leukaemia refractory Neuroblastoma More trials…

    Learn about Rare Diseases

    Leiomyosarcoma recurrent – Treatment Soft tissue sarcoma – Treatment Piriformis syndrome – Trials in Disease Stevens-Johnson syndrome Myelodysplastic syndrome – Trials in Disease Acute respiratory distress syndrome – Basic Information Von Willebrand’s disease – Treatment Mantle cell lymphoma refractory Immunodeficiency congenital – Diagnostics Bronchiolitis obliterans syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Immunostimulants Avatrombopag CHLORMADINONE ACETATE Taurine Lidocaine Hydrochloride Polydextrose Gns561 Paclitaxel HSP-CAR19M Quetiapine Vesleteplirsen Tamuzimod Acetate Tradipitant Setanaxib Ethambutol Hydrochloride L-Histidine Losartan Potassium Cl-Ad-Msc-002 Tomligisiran Caffeine More therapies…

    Learn about Your Condition

    Vulvovaginal discomfort Inclusion body myositis Lymphoma Heart disease congenital Tuberculosis Breast cancer in situ T-cell type acute leukaemia Palpitations Kidney transplant rejection Chronic granulomatous disease Graft infection Pigmentary glaucoma Cardiomyopathy Haematological infection Oesophageal cancer metastatic More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Psoriasis

  • Study on Long-term Safety and Effectiveness of ESK-001 for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Envudeucitinib
    Austria Belgium Bulgaria Czechia Estonia France +7

  • Study on the Effectiveness and Safety of ESK-001 and Apremilast for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Envudeucitinib
    • Apremilast
    Austria Estonia France Germany Hungary Latvia +3

  • Study on the Effects of IDP-118 Lotion (Tazarotene and Halobetasol Propionate) for Children with Moderate to Severe Plaque Psoriasis

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • HALOBETASOL PROPIONATE
    • TAZAROTENE
    Poland

  • Study Comparing CT-P55 and Secukinumab for Moderate to Severe Plaque Psoriasis Patients

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Secukinumab
    Poland

  • Study on the Effectiveness of LY4100511 for Adults with Moderate-to-Severe Plaque Psoriasis

    Not recruiting

    2 1
    Investigated Drugs:
    • Ly4100511
    Czechia Germany Hungary Poland

  • Study on the Effects of Deucravacitinib for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Deucravacitinib
    Germany
Previous Page
1 … 3 4 5 6 7 … 9
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!